OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
March 02, 2021
Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.
February 25, 2021
The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.
February 24, 2021
The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.
February 17, 2021
The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.
The acquisition will allow Charles River to expand its cell and gene therapy development, testing, and manufacturing capabilities, while adding to its existing portfolio of non-clinical capabilities.
February 04, 2021
Catalent will offer materials from its gene therapy facilities in Maryland to support IND-enabling studies and a Phase I/II clinical trial of the product.
January 29, 2021
Biotechnology company, Polyplus-transfection, has started construction of a new facility in France to meet growth in the cell and gene therapy market.
January 28, 2021
Evozyne’s evolution-based protein design technology will be used to research and develop proteins that could be used in the next generation of gene therapies.
January 25, 2021
Through the acquisition, Lilly will have access to Prevail’s portfolio of clinical-stage and preclinical neuroscience assets.
January 20, 2021
Leveraging real-time MRI guidance for intracranial gene therapy administration potentially improves efficacy and outcomes.